Faron Pharmaceuticals' (Faron Pharmaceuticals Oy (AIM:FARN, OTC:FPHAF)) Markku Jalkanen (CEO) talks to Proactive London's Katie Pilbeam about their ongoing biomarker study from a Faron Pharmaceuticals Oy (AIM:FARN, OTC:FPHAF) (Faron Pharmaceuticals Oy (AIM:FARN, OTC:FPHAF), Faron Pharmaceuticals Oy (AIM:FARN, OTC:FPHAF)) phase I/II cancer trial.
He says the results have yielded ‘exciting' findings that should help identify which patients will respond best to its drug bexmarilimab when it is used on its own.
The top-line analysis of the latest patient feedback reveals bexmarilimab ignites a response from those that have not traditionally benefited from current immunotherapy treatments.
